Kimmtrak First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 26
- Publication type:
- Article
Works matching IS 21644403 AND DT 2022 AND VI 12 AND IP 3
Results: 8
1
2
Funding for Healthcare Providers During the Pandemic: An Update.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 20
- By:
- Publication type:
- Article
3
Grouping Denial Codes Can Reduce Financial Loss and Increase Efficiency in Your Practice.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 16
- By:
- Publication type:
- Article
4
Adding Ivosidenib to First-Line Azacitidine Improves Outcomes in Older Patients with AML.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 14
- By:
- Publication type:
- Article
5
Community Providers Share Their Perspectives on Cancer Care.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 8
- By:
- Publication type:
- Article
6
Elacestrant May Improve Outcomes for Patients with Metastatic Breast Cancer Who Have Progressed on Previous Endocrine Therapy.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 1
- By:
- Publication type:
- Article
7
Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 1
- By:
- Publication type:
- Article
8
Exploring the Future of Genetic Therapies and Value-Based Care in Oncology.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 3, p. 1
- By:
- Publication type:
- Article